Recent

% | $
Quotes you view appear here for quick access.

ImmunoCellular Therapeutics, Ltd. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • fansteman fansteman Nov 23, 2012 11:08 AM Flag

    Trial ending Q1 2013?

    IMUC knows it and FDA, too: It will be VERY difficult, even impossible, to run a phase III if mOS is proven to be significantly improved by ICT-107 in the phase II trial. In fact, one could argue that it would be unethical to require another more or less identical trial (because you would withhold an effective, life saving medication from the phase III placebo patients). I reckon, it will go straight into filing if phase II is positive (also at EMA in Europe). Once approved it will define a new standard of care for the 50-75% HLA-A1/A2 positive GBM first-line population: call it a blockbuster.

 
IMUC
0.4799-0.0001(-0.02%)Jul 31 4:00 PMEDT